Bisphosphonates may improve survival of breast cancer patients with disseminated tumor cells in bone marrow
EF Solomayer, M Banys, G Gebauer, N Krawczyk, D Wallwiener, P Hirnle, W Janni, HJ Lück, S Becker, J Huober, B Wackwitz, T Fehm · Senologie - Zeitschrift für Mammadiagnostik und -therapie · 2012 · Heft 06
Bibliografische Angaben
Zusammenfassung
Introduction: The presence of disseminated tumor cells (DTC) in bone marrow (BM) is an independent prognostic factor in breast cancer. In addition, tumor cells are able to survive chemotherapy and their persistence is strongly associated with poor outcome. Bisphosphonates have been previously reported to improve survival in nonmetastatic breast cancer. The purpose of this study was to investigate the impact of zoledronic acid (ZOL) on DTC persistence and patients' survival. Material and methods: In total, 96 DTC positive breast cancer patients were included into this prospective open-label parallel-group study b…
